Introduction
IL-17A (50 ng/ml), alone or in combination with TNF-α (50 ng/ml) in KBM. Medium with stimuli 139 was removed and basal medium was added for 48 hours. Next, HDMECs were seeded in 12-well 140 plates in EGM and 1 day after cells were starved and treated with conditioned medium of 141 keratinocytes, in the presence or not of IL-36RA (R&D Systems, 100 ng/ml) or Sunitinib (Pfizer 142 S.r.l., New York, NY, 400 nM). After 24 hours of stimulation, the number of viable cells was 143 determined by a trypan blue exclusion test. At least three independent experiments were performed. 144 145 Cells were treated as described in the "Cell proliferation" section and HDMEC membrane 146 expression of ICAM-1 was evaluated using allophycocyanin (APC)-conjugated anti-CD54 (ICAM- were analyzed using Bio-Plex Software Manager 6.1. Triplicate wells were used for each condition. 169 Coefficient of variation (CV) of measurements of the whole panel was always lower than 10%. 170 Immunohistochemistry 171 Six-mm punch skin biopsies of three patients with mild-to-severe chronic plaque psoriasis 172 undergoing to pharmacological treatment with the anti-IL-17A antibody Secukinumab (Cosentyx, 173 Novartis Farma S.p.A., subcutaneous injection of 300 mg, once a week after an induction phase) 174 were analyzed by immunohistochemistry. For each patient, biopsies were taken before treatment 175 from lesional (LS) and non-lesional (NLS) skin areas, as well as at LS sites after 8-week treatment. 176 Patients received information and gave their consent to participate to the study. substantial amount of two of the three IL-36 isoforms with their release augmenting upon IL-17A or 205 TNF-α stimulation and even more with their combination (Fig. 1B) . However, IL-36 levels were 206 lower than those secreted by human keratinocytes (Fig. 1C ). Consistently with our recent findings 207 [28] , among all the IL-36 isoforms produced by keratinocytes, IL-36γ amount was significantly 208 higher ( Fig. 1C ) and for these reasons the following experiments were performed with IL-36γ only. (early activation) with IL-17A and gradually declined after 15 min, although its levels remained 226 higher than those observed in untreated cells. After 6 hours (late activation), ERK1/2 227 phosphorylation returned to be high and decreased thereafter (Fig 2A) . Finally, consistently with 230 of STAT3, whereas it strongly induced the phosphorylation of P65 and, at a lower extent, that of 231 ERK1/2 ( Fig 2B) . To investigate the effects of IL-17A and IL-36γ treatment on cytokine and chemokine secretion by 280 HDMECs, we used Bio-Plex Pro TM assays in which several inflammatory molecules could be 13 281 simultaneously analyzed. As a comparison, HDMECs were treated with TNF-α alone or in 282 combination with either IL-17A or IL-36γ. As shown in Table 1 , IL-6, CXCL8, G-CSF CXCL10 283 and CCL2 showed a significant up-regulation upon cell treatment with IL-17 alone, even if to a less 284 extent compared to the secretion due to the TNF-α treatment. Secretion of these five cytokines, 285 together with IL-1RA, was significantly augmented upon stimulation with both IL-17A and TNF-α, 286 with an additive effect in respect to treatment with TNF-α alone. In the IL-36γ assay, we used a different Bio-Plex Pro TM assay kit. As reported in Table 2, treatment   295 with IL-36γ alone up-regulated the secretion of CXCL1 and CXCL8. Consistently with previous 296 data demonstrating the transcriptional induction by IL-36 of CX3CL1, CXCL2, CXCL8, CCL2 297 and IL-6 mRNA in HDMECs [28], we found an up-regulation of the release of these proteins in 298 HDMECs following IL-36 treatment. An additive effect of IL-36γ and TNF-α could be observed 299 for the chemokines CXCL5, CX3CL1, GM-CSF, CXCL1, CXCL2, CXCL8, CXCL10, CCL13, and 300 for the IL-6 cytokine as compared to cells treated with TNF-α alone. To validate these data, HDMECs were treated with IL-17A or IL-36γ, alone or in combination with 309 TNF-α, and ELISA were used to measure the amounts of secreted inflammatory mediators selected 310 from the Luminex assays. Analysis of secreted proteins confirmed most of the results obtained in 311 these assays ( Supplementary Table 1 ).
FACS analysis
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The pro-angiogenic role of IL-17A has been often ascribed to its ability to stimulate skin inhibitor Sunitinib, that blocks the activity of either VEGF or platelet-derived growth factor (PDGF) 344 receptors as well as the signaling associated to CD117/c-kit [34] . We firstly verified the release of 345 IL-36 isoforms and VEGF-A in the supernatants of untreated and cytokine-treated keratinocytes. 346 Accordingly to data reported in Figures 1C and 4A , we found that both IL-36γ and VEGF-A were 347 constitutively released and up-regulated upon IL-17A/TNF-α treatment, whereas IL-36γ was the 348 cytokine mostly released by IL-17A-stimulated keratinocytes in their supernatants (data not shown). 349 As shown in Fig 5A, reducing cell proliferation (Fig. 5A ). In fact, both VEGF-A and IL-36γ are likewise secreted by 362 keratinocytes treated with a combination of TNF-α and IL-17A ( Fig 1A, Fig 4A) 
